It's funny you should mention Peptidream. It would appear that the best-in-class assessment has been made with Peptidream squarely in the frame;
"The [international conferences] provide a compelling indication of the broad market interest in Phylogica's technologies, which are clearly competitive with approaches from our peers in the peptide discovery field such as Bicycle Therapeutics, Peptidream and Ra Pharma."
Its not clear in the sense of the market valuation but it may be clear to Big Pharma as they compare technologies. It brings a focus to your comment in an earlier thread;
"I'm not saying it should be valued at $100m but just that it could be on very little 'apparent' progress when really it was just the cumulative achievement of all work to date being recognised."
PYC Price at posting:
1.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)